Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis.

IMPORTANCE Patients with anti–N-methyl-D-aspartate receptor (NMDAR) encephalitis often develop prominent psychiatric manifestations. The frequency and type of isolated psychiatric episodes (pure psychiatric symptoms without neurological involvement) either as initial presentation of the disease or as relapse are unknown. OBJECTIVE To determine the frequency, symptoms, and outcome of isolated psychiatric episodes in a cohort of patients with anti-NMDAR encephalitis. DESIGN, SETTING, AND PARTICIPANTS Observational cohort of patients diagnosed during a5-year period (median follow-up, 2 years). A total of 571 patients with IgG antibodies against the NR1 subunit of the NMDAR were included in the study. Antibody studies were performed at the University of Pennsylvania and the University of Barcelona, and clinical information was obtained by us or referring physicians. MAIN OUTCOMES AND MEASURES Frequency, type of symptoms, and outcome of patients with anti-NMDAR encephalitis and isolated psychiatric manifestations. RESULTS Of 571 patients, 23 (4%) developed isolated psychiatric episodes, 5 at disease onset and 18 during relapse. For all 23 patients, age (median, 20 years), sex (91%female), and tumor association (43%; ovarian teratoma in all cases) were similar to the population at large.Predominant symptoms included delusional thinking (74%), mood disturbances (70%,usually manic), and aggression (57%). Brain magnetic resonance imaging findings were abnormal in 10 of 22 patients (45%) and cerebrospinal fluid analysis showed pleocytosis in 17 of 22 patients (77%). Eighty-three percent of the patients had full or substantial recovery after immunotherapy and tumor resection when appropriate. After relapse, 17 of 18 patients(94%) returned to a similar or better prerelapse functional level. CONCLUSIONS AND RELEVANCE Isolated psychiatric episodes are rare but can occur as initial onset or relapse of anti-NMDAR encephalitis. Recognition of these episodes is important because they respond to immunotherapy. In patients with new-onset psychosis, having a history of encephalitis, subtle neurological symptoms, and/or abnormal results on ancillary tests should prompt screening for NMDAR antibodies.

[1]  M. Skalej,et al.  Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. , 2013, JAMA psychiatry.

[2]  L. Honig,et al.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study , 2013, The Lancet Neurology.

[3]  C. Ploner,et al.  N‐methyl‐D‐aspartate receptor antibodies in herpes simplex encephalitis , 2012, Annals of neurology.

[4]  K. Berman,et al.  Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. , 2012, The American journal of psychiatry.

[5]  R. Buchert,et al.  IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment , 2012, Neurology.

[6]  A. Coles,et al.  Antibody-mediated encephalitis: a treatable cause of schizophrenia , 2012, British Journal of Psychiatry.

[7]  P. Villoslada,et al.  Analysis of relapses in anti-NMDAR encephalitis , 2011, Neurology.

[8]  J. Dalmau,et al.  Anti-NMDA Receptor Encephalitis in Psychiatry. , 2011, Current psychiatry reviews.

[9]  A. Duchemin,et al.  Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia , 2011, Schizophrenia Research.

[10]  R. Balice-Gordon,et al.  Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis , 2011, The Lancet Neurology.

[11]  A. Pisani,et al.  Bupropion abates dopamine agonist‐mediated compulsive behaviors in Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.

[12]  Peter B. Jones,et al.  Disease-relevant autoantibodies in first episode schizophrenia , 2010, Journal of Neurology.

[13]  D. Kullmann,et al.  N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes , 2010, Brain : a journal of neurology.

[14]  M. Rosenfeld,et al.  Anti–N‐methyl‐D‐aspartate receptor (NMDAR) encephalitis in children and adolescents , 2009, Annals of neurology.

[15]  Xiaoyu Peng,et al.  Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies , 2008, The Lancet Neurology.